News

You can do your everyday shopping and great gift-giving while supporting NTM Info & Research! NTMir is able to sell gift cards with no activation fees to major national and regional retailers. In return, the retailers donate a percentage back to our...

Aradigm, the company that submitted Linhaliq to the FDA for approval, announced that they had received a complete response letter (CRL) from the FDA stating that they would not approve the treatment at this time. Many of you have communicated recently with the FDA...

The voice of the patient has a role in the drug development and approval process. In fact, recent legislation mandates an increased emphasis on incorporating the patient perspective into the drug approval process.

NTM Info & Research and the COPD Foundation is happy to announce the release of the Bronchiectasis and NTM Information Line: 1-833-411-LUNG (5864). The Bronchiectasis and NTM Information Line is a toll-free number managed by the C.O.P.D. Information Line for...

Support Groups come in many different forms. Some are large, some small, some meet monthly, some meet only a few times per year, some meet in person, some are on-line only. There are no rules. We would like to introduce you to a group that has found an innovative...

Our continuing education-accredited conference is a groundbreaking opportunity for health care providers, researchers, patients, families, and caregivers to learn about the latest advances in research, treatment, and care from leaders in the field of nontuberculous...

At the American Thoracic Society International Conference in May, Amy Leitman from NTM Info & Research, along with Dr. Mehdi Mirsaeidi from the University of Miami, presented the results of a survey on geographic diversity of nontuberculous mycobacteria species...

NTM Info & Research (NTMir), the national nonprofit organization advocating on behalf of patients with nontuberculous mycobacterial (NTM) lung disease, applauds the European Commission’s decision to grant marketing authorization for ARIKAYCE® Liposomal 590 mg...

On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM)...